Behind the headlines
Frontotemporal dementia and COVID-19 – insights from the hospital
Kayleigh Watts, from Addenbrooke’s Hospital in Cambridge has worked with people with frontotemporal dementia (FTD) and their loved ones during the Covid-19 pandemic. She reflects on the impact of COVID-19 on those with FTD, in a piece originally written for the Psychologist Magazine.
What does this year’s Nobel Prize mean for dementia research?
With your support, our scientists are looking closely at how DNA changes contribute to the diseases that cause dementia.
Can we really reduce the number of people living with dementia by 40%?
We know that if we can understand what increases the risk of developing dementia, governments and individuals can be better informed about how to reduce that risk.
Behind the headlines: Is a new Alzheimer’s treatment in sight?
The Pharmaceutical company Biogen plans to file for US marketing approval for aducanumab, an experimental treatment for early Alzheimer’s disease.
Behind the headlines: Football and dementia
The results will naturally raise questions from anyone interested in the sport, so here’s everything you need to know about the findings.
In the news: Alzheimer’s drug trial set back
We’re disappointed that Biogen AND Eisai have stopped two phase III trials of Alzheimer’s drug aducanumab. But we’re encouraged by the growing number of new avenues being explored by researchers across the world. Their work has never been more important.
Behind the headlines: Pfizer finds new ways to support dementia research
Pfizer’s move in January was a shifting in research and development priorities to move away from neurodegeneration research carried out in-house in favour of other areas of research, while continuing to invest in other avenues to support neurodegeneration research – like their continued support of the Dementia Discovery Fund.
Alcohol and dementia risk – what we know so far
We know that there are many factors that contribute to dementia risk. There is no surefire way to prevent dementia. Limiting alcohol consumption may be one way to reduce risk but people can develop the condition regardless of alcohol use.
Behind the headlines: Pfizer scales back investment but hope remains for a dementia treatment
Recent news from the pharmaceutical industry that Pfizer is reducing its investment in dementia research has highlighted some of the barriers to research, and the increased need for shared responsibility in bringing treatments to people in need.
